Forgot Password?
Return to Course Listing

CME: At the cutting edge of treatment for advanced diffuse large B-cell lymphoma (DLBCL): Updates in medical management and individualizing patient care


Activity Description / Statement of Need:

In this online, self-learning activity:

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL), making up just under a third of NHL cases. In the United States, there are roughly 7 cases of DLBCL per 100,000 patients per year. The pathophysiology of DLBCL is complex and not fully understood; but is characterized by a widespread increase of very large, mature B-cells arising from various gene mutations. DLBCL is heterogenous group of tumors and includes many diverse subtypes based on location, presence of other cells within the tumor, and whether the patient has other related illnesses. Advanced age, immunodeficiency, and Epstein-Barr virus are associated risk factors for DLBCL. The disease is considered an AIDS-defining malignancy, marking the point at which an HIV infection is considered AIDS. Diagnosis of DLBCL is made by a tissue biopsy, and morphology and immunophenotyping play a crucial role in determining which subtype of DLBCL a patient has.

This learning activity has been designed to bring HCPs’ knowledge of present and emerging strategies for treatment and management of DLBCL up to date and to improve their competence and performance in treating it.

Target Audience:

Hematologists and oncologists; physician assistants, nurse practitioners,  pharmacists who practice in oncology, and any other HCPs with an interest in or who clinically encounter patients with DLBCL.

Commercial Support Disclosure: This program is supported by an educational grant from Genmab and AbbVie.

This activity is free of charge.

Release Date: March 22, 2022 -- Expiration Date: March 22, 2023

Faculty: Ranjit Nair, MD


Faculty introduction, disclosures

Epidemiology and diagnosis of DLBCL

·       Statistics

·       Risk factors, pathophysiology

·       Clinical presentation and staging

·       Pathologic diagnosis and gene expression profiling

·       Double and triple expression, including prognostic implications

Management of DLBCL: Current guidelines, agents, and monitoring

·       Transplant-eligible vs. non-eligible

·       Goals of therapy and monitoring parameters

·       Initial therapy

·       CD-20 targeting

·       Therapy specific to molecular subtype

·       Subpopulations and clinical considerations: Germinal center vs. activated B cell types

·       Special populations: HIV/AIDS, CD20-negative, central nervous system lymphoma

·       Disease progression

·       Chimeric antigen receptor T cells

·       Chemo- and immunotherapy

·       Investigational and emerging therapies

·       Gaps in care

·       Patient cases

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall goals of therapy and monitoring parameters in treating DLBCL
  • Summarize present standards of care for the medical management of DLBCL
  • Describe the mechanisms of action and places in therapy of present and investigational medications for DLBCL
  • Formulate an individualized treatment regimen for a patient with DLBCL


ACCME Activity #201943115


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure:

Ranjit Nair, MD, Assistant Professor, The University of Texas MD Anderson Cancer Center, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Genmab and AbbVie.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Biosimilars in the treatment of malignancies and supportive care

Advances in Treating HER2-Postive Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies

Metastatic colorectal cancer (mCRC) treatment: Therapeutic updates, best practices, and barriers to care

Treatment strategies for hepatocellular carcinoma (HCC): Now, it’s personal(ized)